CD4/CD8 T细胞选择影响嵌合抗原受体(CAR)T细胞效力与毒性:抗CD22 CAR T细胞I期试验更新结果
这项单中心I期3+3剂量递增试验纳入58例复发/难治性CD22阳性恶性肿瘤儿童和年轻成人,评估CD22 CAR T细胞的安全性、毒性、可行性及疗效。CD4/CD8 T细胞选择改善了制备可行性但增加了炎症毒性,导致剂量下调;完全缓解率为70%,中位总生存期为13.4个月。
要点
- 58例输注CD22 CAR T细胞,其中51例(87.9%)既往接受过CD19靶向治疗。
- 细胞因子释放综合征发生于50例(86.2%),其中45例(90%)为1-2级。
- CD4/CD8 T细胞选择改善制备可行性但增加炎症毒性,导致剂量下调。
核心结论
- 在迄今最大规模的CD22 CAR T细胞经验中,提供了制备工艺变化对临床结局影响的新信息,并报告了独特的CD22 CAR T细胞毒性及毒性缓解策略。
- 缓解诱导率支持进一步开发CD22 CAR T细胞作为CD19靶向免疫治疗耐药患者的治疗选择。
研究设计与样本
- 单中心、I期、3+3剂量递增试验,包含大型扩展队列,测试CD22靶向CAR T细胞用于复发/难治性CD22阳性恶性肿瘤儿童和年轻成人。
- 主要目标为评估安全性、毒性和可行性;次要目标包括疗效、CD22 CAR T细胞持续性和细胞因子谱。
主要发现
- 58例参与者输注,其中51例(87.9%)既往接受过CD19靶向治疗。
- 细胞因子释放综合征发生于50例参与者(86.2%),其中45例(90%)为1-2级。
- 神经毒性症状轻微且短暂。
- 19/58例(32.8%)受试者出现噬血细胞性淋巴组织细胞增多症样表现,促使使用阿那白滞素。
- CD4/CD8 T细胞选择采集产物改善了CAR T细胞制备可行性并加重炎症毒性,导致剂量下调。
关键数值与推荐
- 完全缓解率为70%。
- 中位总生存期为13.4个月(95%CI,7.7至20.3个月)。
- 在达到完全缓解者中,中位无复发生存期为6.0个月(95%CI,4.1至6.5个月)。
- 13例参与者后续接受干细胞移植。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort treated with CD22 chimeric antigen receptor (CAR) T cells. PATIENTS AND METHODS: We conducted a single-center, phase I, 3 + 3 dose-escalation trial with a large expansion cohort that tested CD22-targeted CAR T cells for children and young adults with relapsed/refractory CD22+ malignancies. Primary objectives were to assess the safety, toxicity, and feasibility. Secondary objectives included efficacy, CD22 CAR T-cell persistence, and cytokine profiling. RESULTS: Fifty-eight participants were infused; 51 (87.9%) after prior CD19-targeted therapy. Cytokine release syndrome occurred in 50 participants (86.2%) and was grade 1-2 in 45 (90%). Symptoms of neurotoxicity were minimal and transient. Hemophagocytic lymphohistiocytosis-like manifestations were seen in 19/58 (32.8%) of subjects, prompting utilization of anakinra. CD4/CD8 T-cell selection of the apheresis product improved CAR T-cell manufacturing feasibility as well as heightened inflammatory toxicities, leading to dose de-escalation. The complete remission rate was 70%. The median overall survival was 13.4 months (95% CI, 7.7 to 20.3 months). Among those who achieved a complete response, the median relapse-free survival was 6.0 months (95% CI, 4.1 to 6.5 months). Thirteen participants proceeded to stem-cell transplantation. CONCLUSION: In the largest experience of CD22 CAR T-cells to our knowledge, we provide novel information on the impact of manufacturing changes on clinical outcomes and report on unique CD22 CAR T-cell toxicities and toxicity mitigation strategies. The remission induction rate supports further development of CD22 CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy.
引用
- Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. J Clin Oncol. 2020. PMID: 32286905. doi:10.1200/JCO.19.03279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。